This project aims to comprehensively evaluate the role of androgen receptor (AR) signalling in breast cancer by identifying changes in AR signalling and its role in an endocrine resistant setting. Understanding the changes in AR signalling in either treatment-naive or treatment-resistant context would better assist in the identification for opportunities to modulate AR signalling as a therapeutic target in breast cancer.
Integration Of Basic And Translational Genitourinary Cancer Research Into Academic Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Improvements in human health can only occur when the best basic research is tested in the best clinical trials and then applied in clinical practice across the board. Practitioner Fellowships are designed to support people who bridge these areas. This Fellowship will support an integrated program of research involving laboratory studies in prostate cancer, clinical trials in prostate and other types of cancer, application to clinical practice, and high level clinical and research leadership.
Big Data To Inform The Impact Of Antibiotics And Proton Pump Inhibitors On Immunotherapies Used To Treat Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$115,883.00
Summary
Antibiotics and proton pump inhibitors (PPIs) affect gut bacteria health. Gut bacteria are involved in the function of the immune system and potentially the effectiveness of immunotherapies. However, the impact of antibiotics and PPIs on the efficacy of immunotherapies is unknown. Newly available big data will be used to determine the impacts of antibiotics and PPIs on immunotherapy efficacy, informing on the best cancer treatments to use in patients who require antibiotics or PPIs.
Immunotherapy In Mismatch Repair-deficient Colorectal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
A new drug called PD-1 is effective in treating bowel cancers occurring in people at high risk of cancer called Lynch syndrome but little is known why PD-1 is effective at treating these cancer types. Initial studies have found that certain attributes of these cancers such as high amounts of inflammation may help to predict why these cancers respond to PD-1 but further studies of these tumors are needed to identify other tumor characteristics that may help predict responsiveness to PD-1.
Identifying The Missing Heritability Of Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$461,104.00
Summary
One of the strongest risk factors for the development of breast cancer is having a close relative with the disease. Some advances have been made in understanding the specific genetic factors that underlie this susceptibility but these known genetic factors only explain about a third of the overall familial effects. This research will utilise our prior research, international research resources, new technology and supercomputing to identify the majority of genetic factors associated with breast c ....One of the strongest risk factors for the development of breast cancer is having a close relative with the disease. Some advances have been made in understanding the specific genetic factors that underlie this susceptibility but these known genetic factors only explain about a third of the overall familial effects. This research will utilise our prior research, international research resources, new technology and supercomputing to identify the majority of genetic factors associated with breast cancer susceptibility.Read moreRead less
An Ethical Analysis Of Breast Cancer Screening In Australia To Inform Future Practice
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Breast cancer screening is an important part of Australia’s focus on promoting good health. There is, however, increasing confusion about how screening should be offered and some concern about the potential harms of screening. I will analyse the development of breast screening in Australia with a particular focus on ethics, will empirically study current screening practices, and make recommendations about how we should progress in future to ensure that the breast screening program is as ethicall ....Breast cancer screening is an important part of Australia’s focus on promoting good health. There is, however, increasing confusion about how screening should be offered and some concern about the potential harms of screening. I will analyse the development of breast screening in Australia with a particular focus on ethics, will empirically study current screening practices, and make recommendations about how we should progress in future to ensure that the breast screening program is as ethically sound as possible.Read moreRead less
The Role Of Aspirin In The Prevention Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,725,799.00
Summary
ASPREE is a large, phase 3 clinical study of health participants over the age of 70 years who have been randomized to either continuous low dose aspirin or placebo for an average of 5 years. This grant is concerned with collecting long-term follow-up for an additional 5 years, especially for evidence of colorectal cancer (CRC) as well as the exploration of potential mechanisms of action by which aspirin may prevent the development of CRC.
Microfluidic Strategy For Circulating Tumour Cells Analysis In Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$429,180.00
Summary
My approach and ultimate goal over the next 4 years is to demonstrate the use of recently discovered “Nanoshearing” technology as a standard diagnostic tool for cancer patients undergoing systemic therapy and assess the impact of standard protocols in predicting response to therapy and patient outcomes. Data from this study could potentially define new standards of clinical practice, as they relate to follow-up screening for response to therapy and recurrence of disease.
The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinki ....The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinking the tumour.Read moreRead less